Neuren Pharmaceuticals Limited · ASX:NEU
Neuren Pharmaceuticals — Investor Presentation (February 2006)
20 slides from Neuren Pharmaceuticals's investor presentation, February 2006
Slide 1: Neuren Pharmaceuticals Investor Update
Neuren Pharmaceuticals Investor Update February 2006
Slide 2: Disclaimer
Disclaimer This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements
Slide 3: Corporate Overview
Neuren Pharmaceuticals Corporate Overview
Slide 4: Corporate Overview
Corporate Overview Corporate Snapshot Register Neuren is a drug development company targeting NeuronZ Ltd: 11.0% brain repair& rescue, metabolism and cancer NZ Seed Fund Management Ltd: 10.2% Neuren’s lead products protect against brain damage Pfizer Inc: 7.2% Glypromate® has been accelerated into P
Slide 5: Repairing Brain Damage from Aging and Injury
Repairing Brain Damage from Aging and Injury BRAIN INJURY DISEASE Brain cells die acutely Stroke – No blood supply Traumatic Brain Injury – Trauma (TBI) Brain cells die chronically Alzheimer’s Disease – Disease process Parkinson’s Disease – Aging Memory Loss Nervous tissue in the bra
Slide 6: Development Pipeline
Development Pipeline y log cy n o n ca tio ic at io ad ffi u c Tox e 1 e 2 e 3 is Le n al E od al ha s ha s ha s al ry ti o ic Pr ic ci ve ed la l in l P l P l P er o at lin ia Cl ca ca ca m sc li d rm u -C t er e- ni ni ni m Di Va Fo P re M a P r C l i C l i C l i Co • Glypromate® CY2006 • NNZ-2566
Slide 7: Glypromate: Coronary Artery Bypass Graft (CABG) Surgery
Glypromate® Coronary Artery Bypass Graft (CABG) Surgery
Slide 8: Glypromate
Glypromate® Glypromate® is derived from a naturally occurring peptide that is generated by the human brain Glypromate® has the following significant neuroprotection characteristics: – Crosses the blood brain barrier – Long therapeutic window (highly effective when administered 7 – 11 hours after
Slide 9: Glypromate - Neuroprotection in CABG Surgery
Glypromate® - Neuroprotection in CABG Surgery CABG surgery was selected by Neuren because of its drug trial characteristics and excellent commercial prospects: 1. Drug Trial Characteristics • CABG surgery scheduling is timed and known • No ambiguity in diagnosis, base-line cognitive function can b
Slide 10: Glypromate – Development Plan
Glypromate® – Development Plan CY 2005 CY 2006 OCT 2005 Phase 1 completed in Oct 2005 • Demonstrated excellent safety profile in 30 healthy patients Major Milestone MAR/APR 2006 Commenced Phase 2a in Dec 2005 assessing the safety profile in 30 CABG patients • Recruitment complete within next 3-4 wee
Slide 11: Glypromate – Accelerated into Phase 3
Glypromate® – Accelerated into Phase 3 Safety is the key issue governing whether Glypromate® will successfully enter Phase 3 in 2006 Safety considerations have been paramount in design and conduct of Phase 2a trial and preparation for Phase 3 All the evidence to date suggests that Glypromate®
Slide 12: NNZ-2566: Traumatic Brain Injury (TBI)
NNZ-2566 Traumatic Brain Injury (TBI)
Slide 13: NNZ-2566 – First Indication is Traumatic Brain Injury
NNZ-2566 – First Indication is Traumatic Brain Injury NNZ-2566 is a modified version of Glypromate® that resulted from an extensive medicinal chemistry program NNZ-2566 offers additional attractive characteristics including: 1. More Potent 2. Oral bioavailability 3. Longer Acting The first ind
Slide 14: NNZ-2566 has Delivered Excellent Results to Date
NNZ-2566 has Delivered Excellent Results to Date Attractive development arrangement with the US Department of Defence (Walter Reed Army Institute of Research) – Walter Reed Army Institute of Research funds half of the pre-clinical research – Neuren retains all future commercial rights to NNZ-2566
Slide 15: NNZ-2566 Development Plan
NNZ-2566 Development Plan CY 2005 CY 2006 Complete pre-clinical program with Walter Reed • Demonstrated excellent results in all animal studies to date Major Milestone Delivered GMP for drug manufacturing Commence Phase 1 in 1H 2006 • Cost of goods reduced by • Alfred hospital (Melbourne) 75% • 30 p
Slide 16: Pipeline
Pipeline Opportunity to out-license four product lines in near term
Slide 17: Four Near-Term Out-licensing Opportunities
Four Near-Term Out-licensing Opportunities NEU does not have the resources to independently develop its entire pipeline NEU has focused on developing four product lines such that they are attractive near-term out-licensing opportunities – Stable compounds – Excellent manufacturing characteristic
Slide 18: Conclusion
Conclusion Poised for major milestones
Slide 19: Investment highlights - All on Track as per Dec 05
Investment highlights- All on Track as per Dec 05 Glypromate® accelerated to Phase 3 in CY2006 Stage of Development Poised for Major Milestones – Preclinical package completed... SAFE and STABLE NNZ 2566 is entering Phase 1 in 1H CY2006 and will deliver results before the end of the year – Condu
Slide 20: Investment highlights
Investment highlights Very few Australian companies are in Phase 3 trials: Typically Uniquely positioned to fund its prohibitively expensive own Phase 3 Study Neuren in close consultation with the US FDA are structuring a very cost effective Phase 3 trial (first pivotal study = A$10m) Plus tim
Neuren Pharmaceuticals — Investor Presentation (February 2006) on 6ix